|
|
Article: Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO.
- Article from:
- PR Newswire
- Article date:
- April 21, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., April 21 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that preclinical results for two new compounds targeted for the treatment of retinal diseases will be presented during the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 27 - May 1, Ft. Lauderdale, FL.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )
"We are very excited by the potential application of the basic research being conducted by our drug discovery team," said Barry Butler, President and CEO of Sirion Therapeutics, Inc. "Sirion's targeted ...